ABCL - AbCellera Biologics Inc.
IEX Last Trade
2.98
0.030 1.007%
Share volume: 49,447
Last Updated: Fri 27 Dec 2024 08:30:01 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$2.95
0.03
1.02%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-08 | 2023-02-21 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-02-20 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 1.594 B | 1.552 B | 1.541 B | 1.498 B | 1.537 B | 1.512 B | 1.488 B | 1.463 B | |
| Current Assets | 1.144 B | 1.046 B | 1.025 B | 940.653 M | 930.735 M | 919.518 M | 871.985 M | 813.948 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 43.891 M | 46.499 M | 75.413 M | 99.155 M | 64.363 M | 71.232 M | 55.810 M | 56.506 M | |
| Short Term Investments | 43.891 M | 46.499 M | 75.413 M | 99.155 M | 64.363 M | 71.232 M | 55.810 M | 56.506 M | |
| Total Receivables | 52.797 M | 105.964 M | 38.593 M | 20.003 M | 45.678 M | 37.446 M | 30.590 M | 34.419 M | |
| Current Cash | 1.022 B | 868.206 M | 886.485 M | 796.495 M | 795.694 M | 785.840 M | 760.585 M | 698.023 M | |
| Total Non-current Assets | 449.829 M | 506.740 M | 515.416 M | 557.266 M | 606.431 M | 592.672 M | 616.109 M | 649.148 M | |
| Property Plant Equipment | 149.178 M | 200.602 M | 217.255 M | 233.187 M | 259.640 M | 277.209 M | 287.696 M | 306.081 M | |
| Other Assets | 43.842 M | 49.066 M | 46.331 M | 89.845 M | 113.446 M | 80.694 M | 94.244 M | 104.933 M | |
| Intangible Assets | 143.179 M | 142.548 M | 131.502 M | 128.845 M | 126.747 M | 124.076 M | 120.425 M | 118.736 M | |
| Goodwill | 47.806 M | 47.806 M | 47.806 M | 47.806 M | 47.806 M | 47.806 M | 47.806 M | 47.806 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.594 B | 1.552 B | 1.541 B | 1.498 B | 1.537 B | 1.512 B | 1.488 B | 1.463 B | |
| Total liabilities | 380.928 M | 302.237 M | 307.630 M | 289.419 M | 342.339 M | 329.415 M | 335.776 M | 333.183 M | |
| Total current liabilities | 221.140 M | 106.052 M | 118.320 M | 89.591 M | 118.905 M | 110.239 M | 119.013 M | 104.883 M | |
| Accounts Payable | 50.555 M | 17.822 M | 19.347 M | 3.094 M | 3.094 M | 3.094 M | 0.000 | 0.000 | |
| Other liabilities | 92.413 M | 90.451 M | 79.457 M | 89.137 M | 112.177 M | 110.813 M | 114.929 M | 129.947 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 32.759 M | 71.591 M | 76.675 M | 77.265 M | 78.079 M | 75.185 M | 71.222 M | 68.079 M | |
| Other liabilities | 92.413 M | 90.451 M | 79.457 M | 89.137 M | 112.177 M | 110.813 M | 114.929 M | 129.947 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 1.213 B | 1.250 B | 1.233 B | 1.209 B | 1.195 B | 1.183 B | 1.152 B | 1.130 B | |
| Common stock | 284.687 M | 285.323 M | 286.322 M | 287.767 M | 288.906 M | 289.497 M | 290.496 M | 292.724 M | |
| Retained earnings | 429.454 M | 456.078 M | 426.185 M | 386.075 M | 355.547 M | 326.937 M | 279.787 M | 239.177 M |